Rolf Jautelat

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

Markus Follmann, Jens Ackerstaff, Gorden Redlich et al. · Journal of Medicinal Chemistry · 2017 · 189 citations · Full text

Medicinal Chemistry, Heart Failure, Chronic Heart Failure +15

The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (<i>R</i>)‐<i>S</i>‐Cyclopropyl‐<i>S</i>‐(4‐{[4‐{[(1<i>R</i>,2<i>R</i>)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer

Ulrich Lücking, Rolf Jautelat, Martin Krüger et al. · ChemMedChem · 2013 · 173 citations

Aminopyrimidine Zk 304709, Lab Oddity Prevails, Lead Identification +21

From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors

Rolf Jautelat, Thomas Brumby, Martina Schäfer et al. · ChemBioChem · 2005 · 81 citations · Full text

Pharmaceutical Science, Cancer Biology, Pharmaceutical Chemistry +17

Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

Anette Sommer, Charlotte Kopitz, Christoph A. Schatz et al. · Cancer Research · 2016 · 73 citations

Pathology, Tumor Biology, Preclinical Efficacy +16

Directed Synthesis of Nonsymmetrical Bis‐Steroidal Pyrazines and the First Biologically Active Cephalostatin Analogues

Michael Drögemüller, Rolf Jautelat, Ekkehard Winterfeldt · Angewandte Chemie International Edition in English · 1996 · 54 citations

Bioorganic Chemistry, Organic Chemistry, Chemistry +16